Table 1.

Baseline characteristics of matched patient cohorts

Variable	Early	Late	SMD
A: Patients with at least one MSIS-29 measurement during follow-up
n	650	130
Male sex, n (%)	177 (27.2)	34 (26.2)	0.024
Age at onset (mean (SD))	34.36 (9.52)	34.49 (8.85)	0.014
Calendar year (median (IQR))	2011 (2009–2013)	2009 (2007–2011)	0.551
Baseline EDSS (median (IQR))	1.50 (0.81–2.00)	1.50 (0.56–2.00)	0.003
Baseline number of relapses (mean (SD))	0.72 (0.94)	0.75 (0.94)	0.036
Delay to first DMT, years (mean (SD))	0.69 (0.53)	2.63 (0.57)	3.531
B: Patients with at least one EQ-5D measurement during follow-up
n	575	115
Male sex, n (%)	172 (29.9)	32 (27.8)	0.046
Age at onset (mean (SD))	33.72 (8.54)	34.32 (8.75)	0.068
Calendar year at onset (median (IQR))	2012 (2009–2013)	2009 (2007–2012)	0.552
Baseline EDSS (median (IQR))	1.50 (0.62–2.00)	1.50 (1.00–2.00)	0.025
Baseline number of relapses (mean (SD))	0.68 (0.86)	0.72 (0.82)	0.045
Delay to first DMT, years (mean (SD))	0.64 (0.51)	2.62 (0.56)	3.658
C: Patients with at least one EDSS measurement during followup
n	886	179
Male sex, n (%)	256 (28.9)	50 (27.9)	0.021
Age at onset (mean (SD))	35.32 (9.99)	35.23 (9.37)	0.009
Calendar year (median (IQR))	2010 (2007–2013)	2008 (2005–2011)	0.476
Baseline EDSS (median (IQR))	1.50 (0.50–2.00)	1.00 (0.00–2.00)	0.010
Baseline number of relapses (mean (SD))	0.84 (1.10)	0.79 (0.95)	0.041
Delay to first DMT, years (mean (SD))	0.70 (0.52)	2.65 (0.55)	3.612

Baseline EDSS and number of relapses measured 0-2 years following disease onset.

DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; EQ-5D, EuroQol-5 Dimensions; SMD, standardised mean difference.